126 related articles for article (PubMed ID: 3707923)
1. Conformational flexibility and biological activity of salmon calcitonin.
Epand RM; Epand RF; Orlowski RC; Seyler JK; Colescott RL
Biochemistry; 1986 Apr; 25(8):1964-8. PubMed ID: 3707923
[TBL] [Abstract][Full Text] [Related]
2. Deletion sequences of salmon calcitonin that retain the essential biological and conformational features of the intact molecule.
Epand RM; Epand RF; Stafford AR; Orlowski RC
J Med Chem; 1988 Aug; 31(8):1595-8. PubMed ID: 3397998
[TBL] [Abstract][Full Text] [Related]
3. Conformational and biological properties of partial sequences of salmon calcitonin.
Epand RM; Stahl GL; Orlowski RC
Int J Pept Protein Res; 1986 May; 27(5):501-7. PubMed ID: 3733320
[TBL] [Abstract][Full Text] [Related]
4. Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
Taylor JW; Jin QK; Sbacchi M; Wang L; Belfiore P; Garnier M; Kazantzis A; Kapurniotu A; Zaratin PF; Scheideler MA
J Med Chem; 2002 Feb; 45(5):1108-21. PubMed ID: 11855991
[TBL] [Abstract][Full Text] [Related]
5. Biological and physical properties of a model calcitonin containing a glutamate residue interrupting the hydrophobic face of the idealized amphiphilic alpha-helical region.
Green FR; Lynch B; Kaiser ET
Proc Natl Acad Sci U S A; 1987 Dec; 84(23):8340-4. PubMed ID: 2825187
[TBL] [Abstract][Full Text] [Related]
6. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
Houssami S; Findlay DM; Brady CL; Martin TJ; Epand RM; Moore EE; Murayama E; Tamura T; Orlowski RC; Sexton PM
Mol Pharmacol; 1995 Apr; 47(4):798-809. PubMed ID: 7723741
[TBL] [Abstract][Full Text] [Related]
7. The hydrophobic moment of the amphipathic helix of salmon calcitonin and biological potency.
Epand RM; Seyler JK; Orlowski RC
Eur J Biochem; 1986 Aug; 159(1):125-7. PubMed ID: 3743567
[TBL] [Abstract][Full Text] [Related]
8. Study of a series of analogs of salmon calcitonin in which alanine replaces leucine.
Epand RM; Epand RF; Orlowski RC
Eur J Biochem; 1990 Mar; 188(3):633-5. PubMed ID: 2331988
[TBL] [Abstract][Full Text] [Related]
9. Correlations between biological activities and conformational properties for human, salmon, eel, porcine calcitonins and Elcatonin elucidated by CD spectroscopy.
Siligardi G; Samorí B; Melandri S; Visconti M; Drake AF
Eur J Biochem; 1994 May; 221(3):1117-25. PubMed ID: 8181470
[TBL] [Abstract][Full Text] [Related]
10. [Centrally and peripherally induced anorectic actions of salmon calcitonin (sCT) in rats: separation of its novel derivative [Gly8]-sCT].
Nakamuta H; Koida M; Ogawa Y; Orlowski RC
Nihon Yakurigaku Zasshi; 1987 Apr; 89(4):191-5. PubMed ID: 3038715
[TBL] [Abstract][Full Text] [Related]
11. Structural determinants of salmon calcitonin bioactivity: the role of the Leu-based amphipathic alpha-helix.
Andreotti G; Méndez BL; Amodeo P; Morelli MA; Nakamuta H; Motta A
J Biol Chem; 2006 Aug; 281(34):24193-203. PubMed ID: 16766525
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, characterization and in vivo activity of salmon calcitonin coconjugated with lipid and polyethylene glycol.
Cheng W; Lim LY
J Pharm Sci; 2009 Apr; 98(4):1438-51. PubMed ID: 18704953
[TBL] [Abstract][Full Text] [Related]
13. Conformational requirements for activity of salmon calcitonin.
Findlay DM; Michelangeli VP; Martin TJ; Orlowski RC; Seyler JK
Endocrinology; 1985 Sep; 117(3):801-5. PubMed ID: 4017965
[TBL] [Abstract][Full Text] [Related]
14. Biologically potent analogues of salmon calcitonin which do not contain an N-terminal disulfide-bridged ring structure.
Orlowski RC; Epand RM; Stafford AR
Eur J Biochem; 1987 Jan; 162(2):399-402. PubMed ID: 3803393
[TBL] [Abstract][Full Text] [Related]
15. Comparison of reversible and nonreversible aqueous-soluble lipidized conjugates of salmon calcitonin.
Cheng W; Lim LY
Mol Pharm; 2008; 5(4):610-21. PubMed ID: 18481870
[TBL] [Abstract][Full Text] [Related]
16. Biologically active calcitonin analogs which have minimal interactions with phospholipids.
Epand RM; Epand RF; Orlowski RC
Biochem Biophys Res Commun; 1988 Apr; 152(1):203-7. PubMed ID: 3358761
[TBL] [Abstract][Full Text] [Related]
17. NMR investigations of structural and dynamics features of natively unstructured drug peptide - salmon calcitonin: implication to rational design of potent sCT analogs.
Rawat A; Kumar D
J Pept Sci; 2013 Jan; 19(1):33-45. PubMed ID: 23208874
[TBL] [Abstract][Full Text] [Related]
18. Analogue separates biological effects of salmon calcitonin on brain and renal cortical membranes.
Twery MJ; Seitz PK; Nickols GA; Cooper CW; Gallagher JP; Orlowski RC
Eur J Pharmacol; 1988 Oct; 155(3):285-92. PubMed ID: 3266153
[TBL] [Abstract][Full Text] [Related]
19. Modulating calcitonin fibrillogenesis: an antiparallel alpha-helical dimer inhibits fibrillation of salmon calcitonin.
Andreotti G; Motta A
J Biol Chem; 2004 Feb; 279(8):6364-70. PubMed ID: 14594801
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, characterization and in-vivo activity of a novel salmon calcitonin conjugate containing a novel PEG-lipid moiety.
Cheng W; Lim LY
J Pharm Pharmacol; 2010 Mar; 62(3):296-304. PubMed ID: 20487211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
